#USA #New York #AI Technology #AEYE Health #Dr. Zack Dvey-Aharon

AEYE Health's Historic Achievement in Eye Care

In a significant milestone for healthcare innovation, AEYE Health has announced its receipt of the prestigious 2026 Prix Galien USA Award for Best Digital Health Solution. This award, often regarded as the Nobel Prize of biopharmaceutical research, recognizes AEYE Health's pioneering AI technology, AEYE-DS, a rapid and accessible diagnostic tool designed to prevent diabetic blindness.

What is AEYE-DS?

AEYE-DS is the first FDA-cleared, fully autonomous AI solution that allows for quick diabetic eye exams without requiring a physician's interpretation. The technology is designed to make eye care more universally accessible, addressing a major public health issue: diabetic retinopathy, which is the primary cause of blindness in working-age adults. Unfortunately, many at-risk individuals miss crucial screenings due to various barriers, such as costs, availability of specialists, and the inconvenience of scheduling separate appointments.

The Importance of Timely Screening

Diabetic retinopathy can lead to severe vision loss if not detected early. Traditional screening methods often involve long waiting times and significant logistical challenges. AEYE-DS, however, transforms the examination process. By utilizing advanced AI algorithms, it enables primary care providers, including nurses and medical assistants, to conduct eye exams efficiently during routine healthcare visits.

The AEYE-DS technology streamlines the testing process to less than a minute, using only a single image per eye without the need for dilation. As a result, it boasts an impressive imageability of over 99%, leading to effective diagnostics for virtually every patient.

Validation and Recognition

To affirm its efficacy, AEYE-DS underwent extensive validation through three prospective, controlled, multicenter phase-III clinical trials involving over 1,200 patients. The results displayed a sensitivity of 92%-93% and a specificity of 89%-94%, solidifying its place as a trusted screening tool.

Dr. Zack Dvey-Aharon, Co-Founder and CEO of AEYE Health, expressed profound gratitude upon receiving the award, highlighting the symbolic victory it signifies for not only the company but for countless patients whose sight can now be preserved. "This award is more than just recognition; it is about transforming lives and intervening before it’s too late," he stated during the acceptance speech at the gala.

The Future of Eyecare with AEYE Health

Harnessing the momentum generated by AEYE-DS, AEYE Health is now moving forward with AEYE-X, an advanced oculomics platform. This new investigational tool aims to perform comprehensive health assessments through retinal images, targeting various health conditions beyond just visual health.

With an ambitious vision of making advanced diagnostic capabilities accessible, AEYE Health is set to transform the landscape of preventive healthcare. Their integrated solutions not only cover diabetic eye examinations but are evolving to assess broader health conditions, leveraging the promise of AI to protect and enhance health.

Conclusion

The 2026 Prix Galien Award embodies the culmination of AEYE Health's dedication to innovation and patient care. As the technology landscape advances, AEYE Health stands at the forefront, illustrating how AI can bridge gaps in healthcare access and prevention efforts. The ongoing commitment to saving sight—and lives—solidifies AEYE Health's legacy as a leader in medical technology innovation.